ImmuCell Corp (ICCC, Financial), a company in the biotechnology sector, witnessed a significant stock price increase of 10.43%. The stock is currently priced at $4.87 with a trading volume of 401 shares. The company reported a revenue of $6.01 million and a net loss of $701,690, resulting in an earnings per share of -$0.09 and a negative P/E ratio of -9.94.
No institutional ratings are available for ICCC at this time. The biotechnology sector has seen a 1.04% increase overall, with notable activity and price fluctuations in companies like Traws Pharma, Inc., Rapt Therapeutics, Inc., and Cingulate Inc.
ImmuCell Corp focuses on developing products to enhance dairy and beef cattle health. It operates through two segments: Diarrhea, which markets the First Defense product, and Mastitis, which is developing Re-Tain. Most of its revenue is generated from the Diarrhea segment.